Fact Sheet: President Donald J. Trump Announces Lower Drug Prices for All 50 State Medicaid Programs

9/18/2026

Fact Sheets

View Original

Action Summary

MFN Pricing Initiative: All 50 State Medicaid programs will benefit from lower drug prices through agreements that ensure prices match the lowest paid by other developed nations.
Generous Medicaid Payment Model: Pharmaceutical manufacturers will provide rebates on brand-name drugs, covering hundreds of drugs across major classes including oncology, diabetes care, and asthma.
Substantial Savings: The Council of Economic Advisers estimates $64.3B in savings over the next decade, with $36.6B for the Federal government and $27.6B for States, freeing capital for more initiatives.
Direct-to-Consumer Benefits: Through TrumpRx.gov, consumers receive MFN prices on new innovative medicines, resulting in over $700 million saved so far and significant discounts for insured seniors, including access to obesity treatments at $50/month.
Historic Milestones:
- May 12, 2025: Executive Order to align U.S. drug prices with MFN levels.
- July 31, 2025: Letters sent to 17 leading pharmaceutical manufacturers detailing required steps.
- September 30, 2025: First MFN agreement with Pfizer announced.
- December 1 & 19, 2025: Additional international and domestic agreements reached.
- February 5, 2026: Launch of TrumpRx.gov for direct patient discounts.
- August 31, 2026: Nine new agreements with drug manufacturers announced.
Market Impact: Agreements now in place with 26 major pharmaceutical manufacturers, covering 89% of the branded drug market.
Legislative Call-to-Action: President Trump urges Congress to enact the Great Healthcare Plan, targeting lower drug prices, reduced insurance premiums, increased price transparency, and greater accountability for insurance companies.

Risks & Considerations

The Executive Order on Most-Favored-Nation (MFN) pricing for Medicaid could lead to significant changes in the pharmaceutical funding landscape. This may impact research funding and partnerships that Vanderbilt University has with pharmaceutical companies and healthcare providers.
While the MFN pricing might lower drug costs for Medicaid programs, there is a concern that it could also lead to reduced innovation in drug development as pharmaceutical companies might limit investments in new research due to lower profit margins.
The financial implications of the MFN pricing model could shift some responsibilities to states, placing pressure on state budgets. This might indirectly affect higher education funding, including that for Vanderbilt University, depending on how states choose to allocate their resources.
There is a risk that the changes in drug pricing and access could lead to disparities in healthcare access for Medicaid beneficiaries, particularly affecting students and staff involved in health-related programs at Vanderbilt.

Impacted Programs

Vanderbilt University Medical Center may need to adapt its strategies regarding pharmaceutical partnerships and research funding, especially if companies reduce funding for research due to lower profit expectations.
School of Medicine could see a shift in focus for research priorities, especially in areas related to drug development and healthcare access, as the landscape evolves with the new pricing model.
The Health Policy Research Program at Vanderbilt may experience an increased demand for analyses and evaluations of the impacts of these price changes on health outcomes and healthcare delivery.
Vanderbilt’s public health initiatives may need to address the potential disparities created by the MFN pricing, ensuring that vulnerable populations still have access to necessary medications.

Financial Impact

Lower drug prices under the MFN framework could result in significant state and federal savings. However, the reallocation of funds might lead to budget constraints for state-funded programs, including higher education.
Vanderbilt University may need to reassess its funding strategies for research grants, especially if federal funds become more competitive due to shifting priorities in healthcare funding.
As drug prices decrease for Medicaid beneficiaries, there may be a lower demand for certain high-cost medications that typically benefit from research funding, potentially impacting the overall financial landscape for health research at the university.
There might be long-term effects on the university’s tuition revenue and endowment if the healthcare policies lead to broader economic changes that affect student demographics and enrollment patterns.

Relevance Score: 4 (The order presents a need for potential major changes or transformations of programs.)

Key Actions

Vanderbilt’s Medical Center should analyze the implications of the Most-Favored-Nation pricing model for Medicaid on its pharmaceutical procurement strategies. Understanding the changes in drug pricing could lead to cost savings and improved patient care in the university’s healthcare programs.
The Office of Federal Relations should engage with state Medicaid programs to monitor the impact of lower drug prices on healthcare accessibility for low-income populations. This engagement could help inform Vanderbilt’s outreach and support initiatives for vulnerable communities.
The Vanderbilt School of Medicine should consider research opportunities related to the economic effects of the MFN pricing on healthcare delivery and access. This could position Vanderbilt as a leader in healthcare policy research.
The Vanderbilt Center for Health Services Research should evaluate the potential long-term effects of these pricing changes on patient outcomes and healthcare equity, contributing to ongoing discussions on healthcare reform.
The Department of Public Policy should prepare policy briefs that address the implications of the MFN agreements on healthcare access, focusing on how these changes affect the state and local healthcare systems. This can enhance Vanderbilt’s influence in policy discussions.

Opportunities

The executive order presents an opportunity for Vanderbilt’s School of Nursing to expand educational programs aimed at training healthcare professionals to navigate new drug pricing structures, ultimately improving patient care.
Vanderbilt can leverage the increased focus on pharmaceutical pricing to collaborate with local healthcare providers on community health initiatives that address the needs of underserved populations affected by high drug costs.
The emphasis on drug affordability opens avenues for Vanderbilt’s Institute for Medicine and Public Health to conduct studies on patient access to essential medications, generating data that could influence future healthcare policies.
By participating in national discussions around drug pricing and healthcare reform, Vanderbilt can enhance its reputation as a thought leader in these critical areas, potentially leading to increased funding and partnerships.
The growing accessibility of medications under these new agreements allows Vanderbilt’s Health Policy Research Center to evaluate the impact of such changes on health outcomes among different demographics, providing valuable insights for future research and policy recommendations.

Relevance Score: 4 (The executive order requires major process changes to adapt to new drug pricing models affecting healthcare delivery.)

Average Relevance Score: 3.4

Timeline for Implementation

May 12, 2025: President Trump signed an Executive Order directing the Administration to take steps toward implementing MFN drug pricing.
July 31, 2025: Letters were sent to 17 pharmaceutical manufacturers outlining the required actions to lower prescription drug prices.
September 30, 2025: The administration announced the first MFN agreement with Pfizer.
December 1, 2025: An agreement with the U.K. was announced to adjust prescription drug pricing.
December 19, 2025: Nine additional MFN agreements with major pharmaceutical companies were announced.
February 5, 2026: TrumpRx.gov was launched, offering MFN pricing on popular medicines.
August 31, 2026: Nine further agreements with pharmaceutical manufacturers were announced.

The shortest interval relevant to direct implementation is approximately 80 days (from May 12, 2025 to July 31, 2025), which falls within the 60–89 days range.

Relevance Score: 3

Impacted Government Organizations

Department of Health and Human Services (HHS): Responsible for administering Medicaid programs and implementing MFN pricing strategies, affecting drug pricing across all 50 states.
Council of Economic Advisers (CEA): Provides crucial economic analysis and estimates on taxpayer savings and overall economic impacts resulting from the MFN agreements.
Office of the United States Trade Representative (USTR): Involved in negotiating international aspects of the drug pricing agreements, including the arrangement with the United Kingdom.
Department of Commerce: Collaborates in international trade agreements that influence prescription drug pricing adjustments.
Congress: Called upon to enact the Great Healthcare Plan, thereby affecting legislative oversight and long-term healthcare policy reforms.

Relevance Score: 2 (A moderate number of Federal agencies and legislative bodies are impacted by the initiative.)

Responsible Officials

Office of the United States Trade Representative – Tasked with implementing the international aspect of drug pricing reforms as evidenced by the December 1, 2025 announcement regarding the U.K. agreement.
Department of Commerce – Responsible for helping execute the agreements that affect drug pricing in line with MFN principles.
Department of Health and Human Services – Charged with implementing aspects of the Medicaid pricing directives and ensuring that drug rebates and pricing reforms reach beneficiaries.

Relevance Score: 4 (The directives affect the heads of major federal agencies charged with executing national healthcare and trade policies.)